Artículos por temáticas

Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study

Sittironnarit G, Ames D, Bush AI, Faux N, Flicker L, Foster J, Hilmer S, Lautenschlager NT, Maruff P, Masters CL, Martins RN, Rowe C, Szoeke C, Ellis KA; AIBL research group.

Dement Geriatr Cogn Disord. 2011;31(3):173-8. doi: 10.1159/000325171. Epub 2011 Mar 9.

A phase II trial of huperzine A in mild to moderate Alzheimer disease

Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2011 Apr 19;76(16):1389-94. doi: 10.1212/WNL.0b013e318216eb7b.

Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library

Larbanoix L, Burtea C, Ansciaux E, Laurent S, Mahieu I, Vander Elst L, Muller RN.

Peptides. 2011 Jun;32(6):1232-43. doi: 10.1016/j.peptides.2011.04.026. Epub 2011 May 6.

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia

Klunk WE.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S20-36. doi: 10.1016/j.neurobiolaging.2011.09.006.

TGF-β1 pathway as a new target for neuroprotection in Alzheimer's disease

Caraci F, Battaglia G, Bruno V, Bosco P, Carbonaro V, Giuffrida ML, Drago F, Sortino MA, Nicoletti F, Copani A.

CNS Neurosci Ther. 2011 Aug;17(4):237-49. doi: 10.1111/j.1755-5949.2009.00115.x. Epub 2009 Nov 19.

Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology

Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P.

CNS Neurol Disord Drug Targets. 2011 Feb;10(1):57-67. doi: 10.2174/187152711794488665.

Cellular and molecular actions of Methylene Blue in the nervous system

Oz M, Lorke DE, Hasan M, Petroianu GA.

Med Res Rev. 2011 Jan;31(1):93-117. doi: 10.1002/med.20177.

The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease

da Rocha MD, Viegas FP, Campos HC, Nicastro PC, Fossaluzza PC, Fraga CA, Barreiro EJ, Viegas C Jr.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):251-70. doi: 10.2174/187152711794480429.

Chronic divalproex sodium use and brain atrophy in Alzheimer disease

Fleisher AS, Truran D, Mai JT, Langbaum JB, Aisen PS, Cummings JL, Jack CR Jr, Weiner MW, Thomas RG, Schneider LS, Tariot PN; Alzheimer's Disease Cooperative Study.

Neurology. 2011 Sep 27;77(13):1263-71. doi: 10.1212/WNL.0b013e318230a16c. Epub 2011 Sep 14.

Memantine in dementia: a review of the current evidence

Herrmann N, Li A, Lanctôt K.

Expert Opin Pharmacother. 2011 Apr;12(5):787-800. doi: 10.1517/14656566.2011.558006. Epub 2011 Mar 9.

[Tau-targeted drugs for dementia]

Furukawa K.

Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:93-7.

Antioxidant pathways in Alzheimer's disease: possibilities of intervention

Viña J, Lloret A, Giraldo E, Badia MC, Alonso MD.

Curr Pharm Des. 2011 Dec;17(35):3861-4. doi: 10.2174/138161211798357755.

BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity

Evin G, Lessene G, Wilkins S.

Recent Pat CNS Drug Discov. 2011 May 1;6(2):91-106. doi: 10.2174/157488911795933938.

The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics

Pritchard SM, Dolan PJ, Vitkus A, Johnson GV.

J Cell Mol Med. 2011 Aug;15(8):1621-35. doi: 10.1111/j.1582-4934.2011.01273.x.

Multi-target-directed ligands in Alzheimer's disease treatment

Bajda M, Guzior N, Ignasik M, Malawska B.

Curr Med Chem. 2011;18(32):4949-75. doi: 10.2174/092986711797535245.